Evaluation of Urolithin A and Fisetin on Improving Sleep and Aging Biomarkers

Inclusion Criteria: * Aged 30-75 years; * Total score \> 5 points on the Pittsburgh Sleep Quality Index (PSQI) for sleep quality assessment; * Able to use personal mobile devices for WeChat, internet access, and related operations; * Informed about the intervention trial and willing to undergo sleep monitoring and other examinations during the study; * Commitment to consume coffee, strong tea, or alcohol ≤1 time per week during the trial period; Exclusion Criteria: * Participation in any clinical trials or dietary/exercise intervention programs within the past 3 months or concurrently; * Diagnosis of major mental disorders or family history thereof, or current use of psychotropic drugs or mood-regulating medications; * Experiencing major psychological trauma (e.g., death of a close relative, significant financial loss) personally or within the family in the past 3 months; * Severe diseases affecting inflammatory levels and/or endocrine components (e.g., severe obesity, uncontrolled diabetes or poorly controlled blood glucose, myocardial infarction, cerebral infarction); * Current use of hormonal medications, beta-blockers, steroids, non-steroidal anti-inflammatory drugs (NSAIDs), etc.; * Use of medications potentially affecting sleep or aging biomarkers (e.g., melatonin, antidepressants, anxiolytics) within the past 3 months; * Plans for relocation or long-term travel within the next 6 months, which may hinder continuous intervention and follow-up.